Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer
University of Michigan Rogel Cancer Center
University of Michigan Rogel Cancer Center
M.D. Anderson Cancer Center
University of Michigan Rogel Cancer Center
Yonsei University
University Hospital, Essen
China Medical University, China
Peking Union Medical College Hospital
Institut Bergonié
Sun Yat-sen University
Chinese PLA General Hospital
ASLAN Pharmaceuticals
Seoul National University Hospital
Chinese PLA General Hospital
University of Miami
Chinese PLA General Hospital